Does the media favor CRSP or ALLO?

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 8 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.95 beat Allogene Therapeutics' score of 0.80 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or CRSP?

In the previous week, Axsome Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 8 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 1.11 beat CRISPR Therapeutics' score of 0.95 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or BEAM?

In the previous week, Beam Therapeutics had 13 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Beam Therapeutics and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.95 beat Beam Therapeutics' score of 0.69 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or EDIT?

In the previous week, Editas Medicine had 8 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 16 mentions for Editas Medicine and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.95 beat Editas Medicine's score of 0.56 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

CRISPR Therapeutics (CRSP) Competitors

$52.26 -1.19 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$52.08 -0.18 (-0.34%)

As of 07:59 PM Eastern

Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? CRISPR Therapeutics's main competitors and comparable companies include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

CRISPR Therapeutics currently has a consensus price target of $68.06, suggesting a potential upside of 30.22%. Allogene Therapeutics has a consensus price target of $8.30, suggesting a potential upside of 371.59%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 8 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.95 beat Allogene Therapeutics' score of 0.80 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,439.61	-$581.60M	-$4.76	N/A
Allogene Therapeutics	$20K	30,403.12	-$190.89M	-$0.67	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Axsome Therapeutics currently has a consensus price target of $267.60, indicating a potential upside of 26.75%. CRISPR Therapeutics has a consensus price target of $68.06, indicating a potential upside of 30.22%. Given CRISPR Therapeutics' higher possible upside, analysts clearly believe CRISPR Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Axsome Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 8 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 1.11 beat CRISPR Therapeutics' score of 0.95 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.32	-$183.17M	-$3.75	N/A
CRISPR Therapeutics	$3.51M	1,439.61	-$581.60M	-$4.76	N/A

Axsome Therapeutics has a net margin of -24.68% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 11 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,439.61	-$581.60M	-$4.76	N/A
Beam Therapeutics	$139.74M	18.01	-$79.99M	-$0.86	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CRISPR Therapeutics currently has a consensus price target of $68.06, indicating a potential upside of 30.22%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 101.07%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Beam Therapeutics had 13 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Beam Therapeutics and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.95 beat Beam Therapeutics' score of 0.69 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a net margin of -54.75% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market.

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Editas Medicine has a net margin of -157.32% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Editas Medicine	-157.32%	-196.63%	-38.17%

CRISPR Therapeutics presently has a consensus price target of $68.06, indicating a potential upside of 30.22%. Editas Medicine has a consensus price target of $6.00, indicating a potential upside of 126.42%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,439.61	-$581.60M	-$4.76	N/A
Editas Medicine	$40.52M	10.04	-$160.06M	-$0.75	N/A

In the previous week, Editas Medicine had 8 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 16 mentions for Editas Medicine and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.95 beat Editas Medicine's score of 0.56 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

CRISPR Therapeutics (NASDAQ:CRSP) and KALA BIO (NASDAQ:KALA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.28, indicating that its stock price is 328% less volatile than the broader market.

KALA BIO has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,439.61	-$581.60M	-$4.76	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
KALA BIO	N/A	-222.35%	-70.23%

CRISPR Therapeutics presently has a consensus target price of $68.06, indicating a potential upside of 30.22%. KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 205,679.59%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 6 more articles in the media than KALA BIO. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 2 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.95 beat KALA BIO's score of 0.41 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CRISPR Therapeutics	Positive
KALA BIO	Neutral

Summary

CRISPR Therapeutics beats KALA BIO on 12 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.17B	$3.89B	$7.21B	$12.81B
Dividend Yield	N/A	3.63%	2.56%	10.55%
P/E Ratio	-10.98	13.60	272.81	25.11
Price / Sales	1,439.61	1,325.67	618.41	90.53
Price / Cash	N/A	106.61	77.33	51.83
Price / Book	2.59	15.42	10.43	6.18
Net Income	-$581.60M	-$22.82M	$3.49B	$358.18M
7 Day Performance	-7.49%	-3.59%	-2.99%	-2.34%
1 Month Performance	-2.34%	0.88%	0.02%	-2.50%
1 Year Performance	0.87%	43.89%	20.19%	9.87%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	2.3681 of 5 stars	$52.26 -2.2%	$68.06 +30.2%	-0.4%	$5.17B	$3.51M	N/A	460	Gap Down
ALLO Allogene Therapeutics	2.0029 of 5 stars	$1.97 flat	$8.30 +321.3%	+51.8%	$680.62M	$20K	N/A	310
AXSM Axsome Therapeutics	3.9781 of 5 stars	$206.68 flat	$267.60 +29.5%	+67.6%	$10.83B	$638.50M	N/A	380	Positive News
BEAM Beam Therapeutics	2.381 of 5 stars	$29.66 flat	$49.00 +65.2%	+23.6%	$3.06B	$139.74M	N/A	510	News Coverage Analyst Forecast Options Volume
EDIT Editas Medicine	2.24 of 5 stars	$3.23 flat	$6.00 +85.8%	+0.4%	$496.06M	$40.52M	N/A	230	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Do analysts recommend CRSP or ALLO?

Does the media favor CRSP or ALLO?

Which has more volatility & risk, CRSP or ALLO?

Is CRSP or ALLO more profitable?

Which has preferable earnings & valuation, CRSP or ALLO?

Do institutionals & insiders hold more shares of CRSP or ALLO?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Do analysts rate AXSM or CRSP?

Which has more volatility & risk, AXSM or CRSP?

Do institutionals and insiders believe in AXSM or CRSP?

Does the media favor AXSM or CRSP?

Which has stronger earnings and valuation, AXSM or CRSP?

Is AXSM or CRSP more profitable?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Which has preferable earnings and valuation, CRSP or BEAM?

Do insiders & institutionals have more ownership in CRSP or BEAM?

Do analysts recommend CRSP or BEAM?

Does the media refer more to CRSP or BEAM?

Is CRSP or BEAM more profitable?

Which has more risk and volatility, CRSP or BEAM?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Is CRSP or EDIT more profitable?

Do analysts prefer CRSP or EDIT?

Do insiders & institutionals believe in CRSP or EDIT?

Which has stronger earnings & valuation, CRSP or EDIT?

Does the media favor CRSP or EDIT?

Which has more volatility & risk, CRSP or EDIT?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Which has more risk & volatility, CRSP or KALA?

Which has stronger earnings and valuation, CRSP or KALA?

Is CRSP or KALA more profitable?

Do analysts recommend CRSP or KALA?

Do insiders and institutionals believe in CRSP or KALA?

Does the media favor CRSP or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools